After the Buyback: How Much Financing Flexibility Does TASE Really Still Have
After spending NIS 202.4 million on the 2025 buyback and NIS 50.7 million on dividends during the year, TASE still ended 2025 with a NIS 310 million regulatory liquidity surplus and a NIS 550 million capital surplus. But the real flexibility is no longer unlimited: not all headline cash is truly free, parent-level liquidity already required an upstream dividend, and a much larger dividend was approved after year-end.
After The Main Article, The Question Is No Longer About Profit
The main article argued that TASE's recurring revenue engines strengthened in 2025, but that excess cash had already started to be used. This follow-up isolates the other half of that claim: after a NIS 202.4 million buyback, a NIS 50.7 million dividend paid during 2025, and another NIS 144.8 million dividend approved after year-end, how much financing flexibility really remains.
The short answer is that TASE still has a thick cushion, but no longer one that can be treated as endless. At the end of 2025, cash, cash equivalents, and short-term financial assets stood at NIS 494.2 million, the regulatory liquidity surplus stood at NIS 310 million, and the capital surplus above regulatory requirements stood at NIS 550 million. But not all of that cash is actually free: part of the historic settlement-share-sale proceeds is earmarked for technology investments and does not count toward capital and liquidity adequacy, the parent company pulled about NIS 30 million up from a wholly owned subsidiary to keep solo cash positive, and after year-end the board added a large special dividend while also opening the door to another buyback in 2026.
Three non-obvious takeaways frame the whole discussion:
- The balance sheet did not crack. Covenants remain distant, the NIS 120 million credit line stayed unused, and year-end bank debt was only about NIS 90.5 million.
- But headline cash is no longer the same thing as free capital-allocation room. The company explicitly explains that some historical settlement-share-sale proceeds cannot be counted as liquid resources for regulatory capital and liquidity purposes.
- The real test moved into 2026. A NIS 144.8 million dividend has already been approved, and management said it may examine another buyback during 2026.
The 2025 Cash Bridge
To measure financing flexibility here, the right lens is the all-in cash picture, not a normalized cash-generation story. The business itself generated strong cash from operations in 2025: NIS 289.8 million. That is the reason the buyback did not immediately become a balance-sheet-stress story. But once the actual cash uses are added back in, the picture becomes much tighter than the earnings headline suggests.
That bridge makes the shift clear. In 2025 TASE did not just generate cash, it deployed it aggressively: NIS 83.3 million went to investment activity, NIS 202.6 million went to the buyback, NIS 50.7 million went to dividends, NIS 9.1 million went to lease payments, and the debt line shows a net repayment of about NIS 9.7 million after a new NIS 130 million loan and NIS 139.7 million of long-term debt repayments.
This distinction matters because the decline in cash was sharper than the decline in the broader liquid-assets line. Cash and cash equivalents fell from NIS 438.3 million to NIS 371.0 million, while the broader line of cash, cash equivalents, and short-term financial assets fell from NIS 531.4 million to NIS 494.2 million. In other words, part of the cushion shifted from deposits into short-term financial assets, but the total cushion still shrank.
The Cash Exists, But Not All Of It Is Truly Free
The Manikay deal is exactly where a surface-level reading can go wrong. On January 9, 2025, TASE bought back 4,622,028 ordinary shares from Manikay, equal to 4.82% of issued share capital excluding treasury shares, at NIS 43.79 per share, for total consideration of NIS 202.4 million. From a capital-allocation perspective, that was an aggressive move, but it was not executed blindly.
The company makes a crucial point: despite having sufficient liquidity balances, it still took a new NIS 130 million loan on the same day, prepaid an older loan whose remaining balance was about NIS 100 million, and added a one-year NIS 120 million credit facility. Why keep debt and an undrawn line if the cash balance looks full? Because, in the company's own framing, not everything that looks like cash on the balance sheet can be treated as truly deployable liquidity for capital and liquidity adequacy purposes.
The buyback note says this almost explicitly. The remaining proceeds from sales of settlement shares, which are intended to fund technology-system investments, cannot be included as part of the group's liquid resources for purposes of meeting capital and liquidity requirements. That is the heart of the story. The money exists inside the system, but it is not the same thing as a fully free pool that can be redeployed again and again toward distributions.
The second signal is just as important. To maintain a positive cash balance at the parent-company level, a wholly owned subsidiary upstreamed a dividend of about NIS 30 million out of its liquidity surplus. So even if the group as a whole remains very strong, flexibility at the solo parent level already requires active internal cash management.
That chart explains why 2025 is not a distress year, but it is a transition year. Regulatory liquidity surplus actually rose from NIS 172 million to NIS 310 million, while capital surplus fell only from NIS 627 million to NIS 550 million. At the same time, the equity ratio fell from 69% to 64%, and equity dropped by NIS 69.8 million to NIS 651.5 million. So TASE did use its balance sheet, but it did not push it anywhere near danger. It simply moved from a near-inexhaustible surplus story to a strong balance sheet that now needs to be managed.
| Layer | 31.12.2025 | What It Means |
|---|---|---|
| Cash, cash equivalents, and short-term financial assets | NIS 494.2 million | A strong accounting liquidity headline, but not all of it counts as free regulatory room |
| Regulatory liquidity surplus | NIS 310 million | This is the real post-requirement liquidity cushion |
| Capital surplus above regulatory requirements | NIS 550 million | Even after the buyback and dividend, capital headroom remains wide |
| Bank debt at year-end | About NIS 90.5 million | Debt exists, but it does not dominate the story |
| Undrawn corporate credit line | NIS 120 million | Renewed in January 2026 and still kept as backup, not rescue funding |
Debt, Facilities, And Covenant Room
The debt picture is cleaner than the headline of a leveraged buyback might imply. The new loan carries interest at prime plus 0.2%, and amortizes through 36 equal monthly principal payments from February 2025 through January 2028. That is not a bullet wall. It is a steadily declining debt balance. At year-end, the current portion stood at NIS 43.6 million and the long-term portion stood at NIS 46.9 million.
The NIS 120 million facility remained unused even after it was renewed in January 2026 for another year, with only a small reduction in the unused-fee rate from 0.33% to 0.30% per year. That does not read like emergency funding. It reads like an option layer designed to make sure that a good regulatory cushion on paper does not translate into too little solo-company flexibility in practice.
| Covenant | Required Threshold | Actual At 31.12.2025 | Read-Through |
|---|---|---|---|
| Equity-to-assets ratio | Minimum 45% | 65% | 20 percentage points above the floor |
| Debt coverage ratio | Maximum 2.5 | 0.5 | Leverage is far from the limit |
| Debt service ratio | Minimum 1.25 | 6.6 | Debt service capacity is much stronger than required |
If that is combined with the separate NIS 30 million credit line available to the clearing house through the end of 2026, against pledged government bonds, there is another liquidity layer in the system. But that also needs to be read correctly: it is mainly an operational buffer for the clearing infrastructure, not a free corporate piggy bank for additional buybacks. So anyone trying to judge future capital-allocation room should focus first on the NIS 120 million corporate line, the surplus capital and liquidity buffers, and the pace of operating cash rebuild.
What Changed After Year-End
Three events after December 31, 2025 matter more for financing flexibility than another pass over the income statement.
First: on January 5, 2026, the corporate NIS 120 million credit facility was extended for another year, with no economic change other than a modest cut in the unused-fee rate. That signals that TASE wants to keep liquidity optionality open even when it is not actually drawing on it.
Second: on January 13, 2026, the court approved the plaintiff's uncompensated withdrawal and deleted the class-action request linked to the Manikay buyback. The withdrawal request stated that it followed a preliminary court comment that it was difficult to find a basis for an oppression claim in the circumstances. That does not add cash, but it does remove legal friction around the main capital-allocation move of 2025.
Third: on March 5, 2026, the board approved a NIS 144.8 million dividend, including NIS 90.5 million under the regular payout policy and NIS 54.3 million as a special dividend. In the same discussion, management told the board it intended to examine the possibility of another buyback during 2026. This is where the story sharpens. Retained earnings at December 31, 2025 stood at NIS 277.6 million before deducting the dividend approved in March 2026. After that declaration, the accounting distribution buffer drops to roughly NIS 132.8 million.
In other words, after 2025 the question is no longer whether TASE is able to execute another capital move. It is. The question is whether it wants to keep deploying capital before it rebuilds part of the cushion it consumed in 2025. That is now a discipline test, not a technical-capacity test.
Bottom Line
After the buyback, TASE still retains meaningful financing flexibility. It ends 2025 with a NIS 310 million regulatory liquidity cushion, a NIS 550 million capital surplus, an undrawn NIS 120 million corporate line, and debt that amortizes over time rather than hitting a near-term wall. This is not a company that boxed itself into a corner through a buyback.
But it is also no longer a market-infrastructure business that can be read as if every shekel on the balance sheet is equally free for distribution. Part of the cash is effectively tied to technology investments and excluded from regulatory-liquidity calculations, the solo parent already needed an upstream dividend to keep cash positive, and the large March 2026 dividend further shortened the margin for error. So 2026 currently looks less like a surplus year and more like a capital-allocation discipline year: will the operating engine rebuild the cushion, or will TASE try to distribute capital again before cash fully replenishes it?
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.